In a murine Lewis lung carcinoma model, low-dose apatinib alleviated hypoxia, increased lymphocyte infiltration, and reduced PD-L1 expression on the tumor, remodeling the immunosuppressive tumor microenvironment to a more permissive one for antitumor immunity; combining low-dose apatinib with anti-PD-L1 significantly retarded tumor growth, reduced the number of metastases, and prolonged survival of mice [89]. This evidence concerns the gene CD274 and neoplasm.